Spinal Muscular Atrophy Awareness Month

Spinal Muscular Atrophy Awareness Month is observed throughout August to raise understanding of spinal muscular atrophy (SMA), a genetic condition that affects the motor neurons responsible for muscle movement. The observance helps shine a light on the experiences of people living with SMA, their families, and the healthcare professionals and advocates who support them.

Throughout the month, communities come together to share information, encourage earlier recognition and diagnosis, and promote access to care, treatments, and supportive resources. It is also a time to celebrate the strength and achievements of people with SMA while fostering compassion, inclusion, and hope for continued progress in research and treatment.

Spinal Muscular Atrophy Awareness Month is observed throughout August to increase public understanding of spinal muscular atrophy (SMA), a group of inherited neuromuscular disorders that progressively weaken voluntary muscles. SMA affects motor neurons in the spinal cord and is most commonly associated with changes in the **SMN1** gene. The condition has been recognized in medical literature since the late nineteenth century, when physicians Guido Werdnig and Johann Hoffmann described severe childhood-onset forms. Later research identified additional forms, including the milder type described by Erik Kugelberg and Lisa Welander in the 1950s.

The modern history of SMA awareness is closely connected to advances in genetics and patient advocacy. In 1995, researchers identified the SMN1 gene as the primary genetic cause of most cases, transforming diagnosis and scientific research. Families and advocacy organizations, including Cure SMA and other national and international groups, helped bring SMA into broader public discussion by supporting research, educational programs, family services, and efforts to improve early diagnosis. Their work also emphasized that SMA exists across a spectrum of severity and that people living with the condition have varied experiences and abilities.

Awareness efforts gained particular significance as new treatments changed expectations for many patients. The approval of nusinersen in 2016, onasemnogene abeparvovec in 2019, and risdiplam in 2020 represented major milestones in SMA medicine. These therapies grew out of decades of laboratory research and clinical advocacy, while also highlighting the importance of newborn screening, prompt genetic testing, respiratory care, physical therapy, and coordinated support. Awareness campaigns during August help explain both these advances and the continuing challenges of access, affordability, diagnosis, and long-term care.

Culturally, Spinal Muscular Atrophy Awareness Month gives individuals with SMA, families, clinicians, researchers, and advocacy groups a shared opportunity to tell their stories and challenge outdated assumptions about disability. The observance promotes inclusion and recognizes the contributions of people with SMA in education, employment, activism, and community life. By spanning the whole of August, it connects medical education with personal testimony and fundraising, encouraging sustained attention to research and equitable support rather than treating SMA as an issue limited to a single event.